Salmeterol

Generic Name: Salmeterol

Brand Names: Advair, Airduo, Airduo Respiclick, Serevent, Serevent Diskus, Wixela

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 89365-50-4

Unique Ingredient Identifier: 2I4BC502BT

Background: Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.

Salmeterol was granted FDA approval on 4 February 1994.

Indication: 用于哮喘（包括夜间哮喘和运动性哮喘）、喘息性支气管炎和可逆性气道阻塞。

Associated Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Exercise-Induced Bronchospasm

Clinical Trials

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Phase 1

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Fluticasone propionate
Drug: Salmeterol (as xinafoate)

First Posted Date: 2015-06-09

Last Posted Date: 2015-06-09

Lead Sponsor: Intech Biopharm Ltd.

Target Recruit Count: 45

Registration Number: NCT02466503

Locations: 🇨🇳
Clinical Pharmacology Unit of Mackay Memorial Hospital Tamshui Branch, New Taipei City, Taiwan

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Phase 3

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Furoate
Drug: Fluticasone propionate
Drug: Vilanterol
Drug: Salmeterol
Drug: Budesonide
Drug: Formoterol Fumarate

First Posted Date: 2015-05-18

Last Posted Date: 2019-01-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 423

Registration Number: NCT02446418

Locations: 🇩🇪
GSK Investigational Site, Magdeburg, Germany

Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Glycopyrronium MDI
Drug: Placebo
Drug: Serevent Diskus 50 μg

First Posted Date: 2015-05-05

Last Posted Date: 2017-07-02

Lead Sponsor: Pearl Therapeutics, Inc.

Target Recruit Count: 248

Registration Number: NCT02433834

Locations: 🇺🇸
Pearl Therapeutics Inc., Waco, Texas, United States

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)

Phase 3

Completed

Conditions: Central Abdominal Bulging

Interventions: Drug: LIPO-202
Drug: Placebo

First Posted Date: 2015-03-25

Last Posted Date: 2019-01-07

Lead Sponsor: Evofem Inc.

Target Recruit Count: 793

Registration Number: NCT02398188

Locations: 🇺🇸
Society Hill Dermatology, Philadelphia, Pennsylvania, United States
🇺🇸
Wake Research Associates, Raleigh, North Carolina, United States
🇺🇸
Zel Skin & Laser Specialist, LLC, Edina, Minnesota, United States

and more 32 locations

An Open-Label Study to Evaluate Retreatment With LIPO-202

Phase 2

Conditions: Central Abdominal Bulging

Interventions: Drug: LIPO-202

First Posted Date: 2015-03-25

Last Posted Date: 2015-08-13

Lead Sponsor: Neothetics, Inc

Target Recruit Count: 150

Registration Number: NCT02397525

Locations: 🇺🇸
AboutSkin Dermatology, Englewood, Colorado, United States
🇺🇸
DermResearch Center of New York, Stony Brook, New York, United States
🇺🇸
Dermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States

and more 5 locations

Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat

Phase 3

Completed

Conditions: Central Abdominal Bulging

Interventions: Drug: Placebo
Drug: LIPO-202

First Posted Date: 2015-03-25

Last Posted Date: 2016-01-08

Lead Sponsor: Neothetics, Inc

Target Recruit Count: 800

Registration Number: NCT02397499

Locations: 🇺🇸
Skin Care Research, Inc., Boca Raton, Florida, United States
🇺🇸
Clinical Testing Center of Beverly Hills, Beverly Hills, California, United States
🇺🇸
Clinical Science Institute, Santa Monica, California, United States

and more 28 locations

Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD

Phase 3

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Salmeterol / fluticasone (Seretide®)
Drug: Bufeijianpi granule
Drug: Placebo Bufeijianpi granule
Drug: Bufeiyishen granule
Drug: Placebo Bufeiyishen granule
Drug: Placebo Yiqizishen granule
Drug: Yiqizishen granule